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Abstract
Background Dermoscopy is a widely used technique that can increase the sensitivity and specificity of melanoma
detection. Information is lacking on the impact of dermoscopy use on the detection of melanoma in the real-life practice
of European dermatologists.
Objective To identify factors that influence the benefit of using dermoscopy for increasing melanoma detection and
lowering the number of unnecessary biopsies in the practice of European dermatologists.
Methods We conducted a survey of dermatologists registered in 32 European countries regarding the following: the demo-
graphic and practice characteristics, dermoscopy training and use, opinions on dermoscopy and the self-estimated impact of
dermoscopy use on the number of melanomas detected and the number of unnecessary biopsies performed in practice.
Results Valid answers were collected for 7480 respondents, of which 6602 reported using dermoscopy. Eighty-six per
cent of dermoscopy users reported that dermoscopy increased the numbers of melanomas they detected, and 70%
reported that dermoscopy decreased the number of unnecessary biopsies of benign lesions they performed. The derma-
tologists reporting these benefits were more likely to have received dermoscopy training during residency, to use der-
moscopy frequently and intensively, and to use digital dermoscopy systems and pattern analysis compared to
dermatologists who did not perceive any benefit of dermoscopy for the melanoma recognition in their practice.
Conclusions Improving dermoscopy training, especially during residency and increasing access to digital dermoscopy
equipment are important paths to enhance the benefit of dermoscopy for melanoma detection in the practice of Euro-
pean dermatologists.






Dermoscopy is an established tool for the clinical diagnosis of a
wide range of skin diseases,1–8 but its main role remains the
facilitation of melanoma diagnosis. Dermoscopy used by trained
physicians has been shown to increase the sensitivity of mela-
noma detection up to ninefold compared to the clinical exami-
nation alone.9–11 Moreover, it allows for the earlier detection of
thinner melanomas12,13 by revealing subtle changes of melanocy-
tic lesions, invisible to the naked eye. As such, it is a valuable aid
for melanoma screening and for the monitoring of high-risk†Eurodermoscopy Working Group members details are in Appendix 1.
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patients, which is recommended by the current practice guideli-
nes for melanoma diagnosis.14–17 At the same time, multiple
studies have shown that dermoscopy use at an expert level can
increase the specificity of melanoma diagnosis, which translates
into the reduction in unnecessary biopsies of benign lesions.18–20
These results are supported by indirect evidence from the analy-
sis of dermatological practices,20–22 where the number needed to
excise (NNE), calculated as the number of all melanocytic
lesions excised for each confirmed melanoma, reportedly
decreases from 20 to 40 in general dermatology practices to 4–8
in specialized skin cancer clinics using dermoscopy.
The proven capacity of dermoscopy to increase the diagnostic
accuracy for melanoma suggests that this technique, if used sys-
tematically, could have a population-wide impact, by improving
early detection and hence the prognosis of melanoma, while reduc-
ing the need for invasive diagnostic procedures and their related
human and material costs. So far, most evidence on the impact of
dermoscopy on melanoma early detection comes from controlled
studies in several expert centres, involving a limited number of
dermatologists. However, very little is known on how dermoscopy
actually impacts everyday dermatology practice in Europe18,23 and
on the factors that enhance or limit the benefits that dermatolo-
gists derive from its use regarding melanoma diagnosis.
In this context, we conducted the first pan-European survey
of the patterns, motivations and obstacles of dermoscopy use.
Herein, we explored the perceptions of European dermatologists
about the benefits of dermoscopy in increasing their capacity to
detect melanomas and reducing the number of unnecessary
biopsies. We analysed further the demographic, practice- and
training-related factors that influence these perceptions.
Methods
The Eurodermoscopy pan-European survey of dermatologists
was conducted under the auspices of the International Der-
moscopy Society (IDS), and its methodology and detailed data
handling were described in detail elsewhere.24 In brief, the study
instrument consisted of a 20-item questionnaire,24 covering
demographic, practice-related and dermoscopy training charac-
teristics, and including questions about the patterns of use and
dermatologists’ attitudes and opinions about dermoscopy. The
questionnaire did not include any personal identification infor-
mation and was translated in all the participating countries’ lan-
guages. It was intended for all licensed dermatologists registered
in European countries and was administered as an online survey
in 32 participating countries. The dissemination of the survey in
each country occurred through the national contact databases of
dermatologists, under the responsibility of National Coordinat-
ing Teams, who collaborated with national dermatology and
dermoscopy professional associations and were led by a National
Coordinator elected from the members of the IDS Board of
Directors or the Country Coordinators of Euromelanoma cam-
paign. Online responses were collected through the IDS web-
based tool for online surveys, into an access-restricted central
database, grouped by country access code. Data cleaning of the
study database was performed by three independent investiga-
tors (GG, AMF and PT).
The current work focuses on the answers to questions regard-
ing the opinion of dermatologists on the impact of dermoscopy
in increasing melanoma detection and reducing the number of
unnecessary biopsies in their daily practice.
For statistical analysis, R software25 was used. Comparing pro-
portions of two groups’ chi-squared test and comparing propor-
tions of ordered groups’ chi-squared test for trends in
proportions were used. Continuous data are given as means and
standard deviations unless stated otherwise, and parametric tests
for comparing groups were only used if corresponding assump-
tions were met. For multivariate analysis, all variables significant
in univariate analysis were entered to a model with backwards
elimination, controlled for sex, age, years in practice and num-
bers of (skin cancer and overall) patients per month. Remaining
significant predictors are given as odds ratios (OR) with 95%
confidence intervals (CI). A P-value < 0.05 was regarded statisti-
cally significant. In univariate analyses P-values were adjusted by
the method of Holm.26
Results
We collected 8519 responses from 32 countries in which a total
number of 38 300 dermatologists were registered as for the year
2014. After the data cleaning, 7480 valid responses were retained
for analysis, of which 6602 reported to use dermoscopy. These
were further analysed to assess the perceived impact of der-
moscopy on the number of detected melanomas and on the
number of unnecessary biopsies of benign lesions.
Factors associated with a perceived benefit of
dermoscopy use in improving recognition of melanoma
Eighty-six per cent of all 6602 dermoscopy users reported that
dermoscopy improved their ability to recognize melanoma com-
pared with the naked-eye clinical examination (Table 1a). This
positive perception showed a statistically significant association
with younger age, working in public healthcare facilities, shorter
duration of practising dermatology, higher number of patients
seen/month, with receiving dermoscopy training during resi-
dency, and having trained in dermoscopy by any interactive
form of education (courses, online courses, conferences, training
with mentor/tutor) (Table 1a). It was also associated with the
use of polarized light dermoscopy and digital dermoscopy, and
with more frequent use of dermoscopy in their practice
(Table 1b). Dermatologists who felt that dermoscopy improved
their melanoma recognition were more likely to use the ABCD
rule and pattern analysis than dermatologists who did not per-
ceive a benefit of dermoscopy in increasing melanoma detection
(31% vs. 26% and 31% vs. 25%, respectively, P = 0.01). Using
no particular algorithm regularly was reported by 41% of
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Table 1 Factors associated with the perception that dermoscopy use improved melanoma recognition in the daily practice. (a) Demo-
graphic and practice setting factors associated with the perceived benefit of dermoscopy in the recognition of melanoma in the daily
practice. (b) Practice factors associated with a perceived benefit of dermoscopy for the recognition of melanoma in the daily practice
(a) Do you feel that using dermoscopy has increased the number of melanomas that
you detected, in comparison with the naked-eye examination?
Yes No P-value
N = 6228 5373 (86.27%) 855 (13.73%)
Female participants 67.23%, n = 3594 67.37%, n = 574 1.000
Age (mean) 46.6 (SD: 10.93) 49.37 (SD: 10.98) <0.001
Place of work
Individual private practice 36.57%, n = 1965 49.12%, n = 420 <0.001
Private ambulatory hospital 19.75%, n = 1061 21.99%, n = 188 0.702
Public ambulatory hospital 31.92%, n = 1715 23.27%, n = 199 <0.001
University hospital 21.11%, n = 1134 22.81%, n = 195 0.836
Involved in teaching for dermatology residents 12.99%, n = 698 12.28%, n = 105 1.000
Years as dermatology specialist (mean) 15.79 (SD: 10.63) 18.53 (SD: 10.68) <0.001
No. of patients seen/month (mean) 442.84 (SD: 413.95) 395.71 (SD: 323.73) 0.002
No. of skin cancer patients seen/month (mean) 61.02 (SD:102.64) 51.69 (SD:140.91) 0.413
Dermoscopy training during residency 44.72%, n = 2374 24.11%, n = 203 <0.001
Types of dermoscopy training received outside residency
Dermoscopy course 66.65%, n = 3581 45.61%, n = 390 <0.001
Online dermoscopy course 19.17%, n = 1030 13.45%, n = 115 0.001
Attended conferences/congresses 73.14%, n = 3930 66.78%, n = 571 0.002
Books/atlases 81.00%, n = 4352 77.43%, n = 662 0.163
Mentor/tutor 24.49%, n = 1316 16.73%, n = 143 <0.001
No training 3.03%, n = 163 4.33%, n = 37 0.413
(b) Do you feel that using dermoscopy has increased the number of melanomas
that you detected, in comparison with the naked-eye examination?
Yes No P-value
Duration of dermoscopy practice
<2 years 10.74%, n = 575 11.87%, n = 101 0.256
2–5 years 19.56%, n = 1047 22.91%, n = 195
>5 years 69.70%, n = 3731 65.22%, n = 555
Types of dermoscopes used
Non-polarized immersion contact 53.17%, n = 2857 57.08%, n = 488 0.294
Polarized light dermoscope 53.97%, n = 2900 47.72%, n = 408 0.008
Dermoscope with digital camera 24.01%, n = 1290 14.62%, n = 125 <0.001
Digital videodermatoscopy system 27.55%, n = 1480 15.56%, n = 133 <0.001
Average frequency of using dermoscopy
<19/month 0.84%, n = 45 1.29%, n = 11 <0.001
1–4/month 3.86%, n = 207 6.44%, n = 55
>19/week 10.39%, n = 557 13.47%, n = 115
Daily 84.91%, n = 4553 78.81%, n = 673
Regularly used dermoscopic algorithm
ABCD rule 31.23%, n = 1678 25.50%, n = 218 0.011
CASH 0.69%, n = 37 0.35%, n = 3 1.000
Menzies algorithm 2.62%, n = 141 2.57%, n = 22 1.000
Seven-point checklist 8.32%, n = 447 5.73%, n = 49 0.137
Pattern analysis 31.01%, n = 1666 24.91%, n = 213 0.005
No particular algorithm 27.40%, n = 1472 41.05%, n = 351 <0.001
P values <0.05 are highlighted in bold.
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dermatologists who did not feel that dermoscopy improved their
melanoma detection ability, compared to 27% of those who
considered dermoscopy to be useful for increased melanoma
detection (P < 0.001) (Table 1b). Dermatologists who reported
a benefit of dermoscopy in increasing their melanoma detection
reported higher self-confidence in their dermoscopic diagnostic
skills for all categories of inflammatory and neoplastic skin dis-
eases and were more likely to have positive opinions about der-
moscopy’s utility and benefits for the practice (Table S1,
Supporting Information), in comparison with the dermatolo-
gists who did not consider that dermoscopy use increased the
melanoma detection in their practice.
In multivariate analysis, the following factors remained signif-
icantly associated with perceived improvement of melanoma
recognition (Table 2): working in a public healthcare facility,
dermoscopy training during residency, receiving any kind of
dermoscopy training except atlases/books, positive opinion
about the utility of dermoscopy in monitoring non-melanocytic
lesions and self-confidence in the assessment of pigmented
lesions. Dermatologists who did not use any particular algorithm
were less likely to perceive a benefit of dermoscopy in increasing
melanoma detection (OR 0.814, 95% CI: 0.675–0.985).
Factors associated with the perceived benefit of
dermoscopy in reducing the number of unnecessary
biopsies
The majority (70.7%) of dermoscopy users observed that der-
moscopy allowed them to reduce the number of unnecessary
biopsies of benign lesions (Table 3a). This positive perception
was associated with the following: working in private practice or
in university hospitals, shorter duration of practising dermatol-
ogy, higher number of patients and skin cancer patients seen per
month, having received dermoscopy training during residency
and having received dermoscopy training in the form of courses,
conferences or atlases/books (Table 3a). It was associated also
with longer dermoscopy practice, with the use of polarized light
dermoscopy and of digital dermoscopy, with more frequent use
of this technique and with using pattern analysis for the dermo-
scopic diagnosis (Table 3b). Use of the ABCD rule or using no
particular algorithm at all was reported more frequently by der-
matologists who have not perceived any benefit of dermoscopy
in reducing biopsies (Table 3b). Further, self-confidence in the
dermoscopic skills for all categories of inflammatory and
tumoral skin diseases, and positive opinions about dermoscopy’s
advantages for the practice were associated with a perceived ben-
efit of dermoscopy in decreasing the number of unnecessary
excisions (Table S2, Supporting Information).
In multivariate analysis, the following factors remained signif-
icantly associated with perceived reduction in the number of
unnecessary biopsies (Table 4): working in private practice,
shorter duration of practising dermatology, training in der-
moscopy in the form of attending conferences, longer duration
of practising dermoscopy and more frequent use of this tech-
nique, use of digital dermoscopy devices and self-confidence in
the dermoscopic diagnostic skills for pigmented lesions. Using
the ABCD rule or no particular algorithm decreased the
Table 2 Factors associated with a perceived benefit of dermoscopy for the improvement of melanoma recognition in the daily practice
(multivariate analysis)
Dermoscopy use increased detected melanoma OR 2.5% CI 97.5% CI P-value
Place of work
Individual private practice 0.791 0.640 0.977 0.029
Private ambulatory/hospital 0.736 0.585 0.929 0.009
Public ambulatory/hospital 1.573 1.269 1.959 <0.001
Dermoscopy training during residency 1.485 1.198 1.847 <0.001
Dermoscopy training
Dermoscopy course 1.611 1.336 1.942 <0.001
Online dermoscopy course 1.362 1.057 1.773 0.019
Attended Congresses 1.293 1.056 1.580 0.012
Mentor/Tutor 1.353 1.073 1.717 0.012
Regularly used dermoscopic algorithm
No used algorithm 0.814 0.675 0.985 0.033
Opinion on the utility of dermoscopy in the following situations
Follow-up of non-melanocytic skin lesions* 1.659 1.347 2.046 <0.001
Self-confidence in the dermoscopic diagnosis of
Pigmented skin tumours* 1.626 1.175 2.232 0.003
Perceived advantages of dermoscopy use
Increases confidence of clinical diagnosis* 2.361 1.141 5.015 0.022
Reduces the number of unnecessary biopsies/excisions * 1.769 1.311 2.369 <0.001
OR, odds Ratio; CI, confidence interval.
*Variables with a calculated linear correlation.
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Table 3 Factors associated with perceived benefit o dermoscopy in reducing unnecessary benign biopsies. (a) Demographic factors
associated with the perceived benefit of dermoscopy in reducing the number of unnecessary biopsies of benign lesions. (b) Practice fac-
tors associated with perceived benefit of dermoscopy in reducing unnecessary biopsies of benign lesions
(a) In your practice, how did the use of dermoscopy influence the number of
excisions of benign lesions that you performed?
Reduced excisions
of benign lesions
Did not reduce excisions
of benign lesions
P-value
N 4406 (70.76%) 1820 (29.24%) NA
Female participants 66.36%, n = 2906 69.33%, n = 1259 0.178
Age (mean) 47.09 (SD: 10.81) 46.74 (SD: 11.4) 0.884
Place of work
Individual private practice 40.06%, n = 1765 34.45%, n = 627 <0.001
Private ambulatory/hospital 18.02%, n = 794 25.11%, n = 457 <0.001
Public ambulatory/hospital 29.05%, n = 1280 34.56%, n = 629 <0.001
University hospital 22.47%, n = 990 18.35%, n = 334 0.004
Involved in teaching activity for dermatology residents 13.12%, n = 578 12.31%, n = 224 0.884
Years as dermatology specialist (mean) 15.94 (SD: 10.54) 16.79 (SD: 11.01) 0.044
Patients seen/month (mean) 459.02 (SD: 418.65) 384.17 (SD:357.31) <0.001
Skin cancer patients seen/month (mean) 66.47 (SD: 114.12) 43.21 (SD: 92.11) <0.001
Dermoscopy training during residency 44.94%, n = 1954 34.33%, n = 618 <0.001
Types of dermoscopy training received outside residency
Dermoscopy course 67.48%, n = 2973 54.73%, n = 996 <0.001
Online dermoscopy course 18.86%, n = 831 17.36%, n = 316 0.884
Attended congresses 75.44%, n = 3324 64.89%, n = 1181 <0.001
Books atlases 81.59%, n = 3595 77.86%, n = 1417 0.008
Mentor tutor 23.88%, n = 1052 22.25%, n = 405 0.884
No training 2.59%, n = 114 4.73%, n = 86 <0.001
(b) In your practice, how did the use of dermoscopy influence the number of
excisions of benign lesions that you performed?
Reduced excisions of
benign lesions
Did not reduce excisions
of benign lesions
P-value
Duration of dermoscopy practice
<2 years 7.25%, n = 318 19.67%, n = 357 <0.001
2–5 years 17.98%, n = 789 24.85%, n = 451
>5 years 74.77%, n = 3280 55.48%, n = 1007
Types of dermoscopes used
Non-polarized immersion contact 52.81%, n = 2327 55.88%, n = 1017 0.178
Polarized light dermoscope 56.20%, n = 2476 45.66%, n = 831 <0.001
Dermoscope with digital camera 24.26%, n = 1069 18.90%, n = 344 <0.001
Digital videodermatoscopy system 29.23%, n = 1288 17.75%, n = 323 <0.001
Average frequency of using dermoscopy
<19/month 0.48%, n = 21 1.82%, n = 33 <0.001
1–4/month 2.39%, n = 105 8.64%, n = 157
>19/week 8.51%, n = 374 16.45%, n = 299
Daily 88.63%, n = 3896 73.10%, n = 1329
Regularly used dermoscopic algorithm
ABCD rule 27.71%, n = 1221 36.98%, n = 673 <0.001
CASH 0.61%, n = 27 0.71%, n = 13 0.884
Menzies algorithm 2.88%, n = 127 1.92%, n = 35 0.266
Seven-point checklist 8.37%, n = 369 6.87%, n = 125 0.308
Pattern analysis 33.66%, n = 1483 21.92%, n = 399 <0.001
No particular algorithm 27.78%, n = 1224 32.86%, n = 598 0.001
P values <0.05 are highlighted in bold.
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likelihood to report a benefit of dermoscopy in reducing unnec-
essary excisions (OR 0.66, 95% CI: 0.56–0.78 and OR 0.70, 95%
CI: 0.59–0.83, respectively).
Discussion
The ultimate goal of dermoscopy for melanocytic lesions is to
increase the early recognition of melanoma while reducing the
number of invasive procedures needed for diagnosis. The capac-
ity of dermoscopy to achieve this goal, increasing the sensitivity
and specificity of melanoma diagnosis, has been solidly docu-
mented in multiple studies.9,10,27 Hence, it is natural to hypothe-
size that making more widespread and better use of this
accessible and affordable technique could have an impact at
population-based scale, on improving melanoma prognosis
through earlier detection, while reducing diagnostic costs. Test-
ing this hypothesis is challenging and first requires understand-
ing the current place and impact of dermoscopy in the real-life
dermatology practice, as well as the drivers and barriers for
future improvement. Our study performed the largest survey of
dermatologists so far, as a step towards this understanding.
Our results confirm at pan-European scale that dermoscopy is
a useful tool for the practice of dermatologists, allowing them to
detect more melanomas and to reduce the number of unneces-
sary benign excisions performed. Our findings reinforce the cru-
cial importance of proper training in translating the potential
advantages of dermoscopy into real benefits for melanoma diag-
nosis. Notably, dermoscopy training during residency almost
doubled the proportion of dermatologists reporting that
dermoscopy allowed them to detect more melanomas than
naked-eye examination alone (Table 1a), and this effect was
maintained in the multivariate analysis (OR 1.51, 95% CI: 1.22–
1.88) (Table 2). Residency dermoscopy training also related,
although less markedly, to the reported benefit of dermoscopy in
reducing the number of unnecessary biopsies.
To our knowledge, this is the first study that explores the
impact of dermoscopy training during dermatology residency on
the subsequent dermatology practice across Europe. Dermoscopy
training during residency has been shown to improve the opin-
ions about dermoscopy, increase the self-confidence in the skin
cancer diagnosis and improve the diagnostic accuracy of derma-
tology residents in USA.28–31 Such studies were lacking in Eur-
ope. Dermatology residency curricula are diverse across the
European continent, not all include dermoscopy training or have
included it only recently, and the actual form of training is also
highly heterogeneous. Given that dermoscopy training is rela-
tively new, it is notable that 38% of all European dermatologists
participating in our study reported dermoscopy training during
residency.
In our study, dermatologists who trained in dermoscopy
through interactive methods (courses, conferences, mentoring/
tutoring) were more likely (OR 1.36–1.64, Table 2) to report
increased melanoma recognition through dermoscopy, while
this effect was not seen for training through atlases/books. This
trend was less clear in regard to the reduction in unnecessary
biopsies, and further research on the most efficient forms of der-
moscopy training for melanoma diagnosis is warranted.
Table 4 Factors associated with a perceived benefit in reducing excisions of benign lesions (multivariate analysis)
Dermoscopy-reduced excisions of benign lesions OR 2.5% CI 97.5% CI P-value
Age 1.029 1.013 1.045 <0.001
Number of years of dermatology practice 0.963 0.948 0.978 <0.001
Place of work
Individual private practice 1.211 1.031 1.423 0.020
Private ambulatory hospital 0.836 0.704 0.994 0.042
Type of dermoscopy training received outside residency
Attended congresses 1.170 1.001 1.365 0.047
Duration of dermoscopy practice* 1.552 1.300 1.852 <0.001
Types of dermoscopes used
Dermoscope with digital camera 1.188 1.006 1.406 0.044
Digital videodermatoscopy system 1.274 1.073 1.515 0.006
High frequency of using dermoscopy* 1.691 1.068 2.709 0.026
Particular dermoscopic algorithm regularly used
ABCD rule 0.666 0.564 0.786 <0.001
No used algorithm 0.707 0.598 0.835 <0.001
Self-confidence in the dermoscopic assessment of the following
Pigmented skin tumours* 1.430 1.078 1.899 0.013
Inflammatory skin lesions* 0.707 0.611 0.820 <0.001
Perceived advantages of dermoscopy use
Reduces the number of unnecessary biopsies/excisions* 5.396 4.023 7.384 <0.001
OR, odds ratio; CI, confidence interval.
*Variables with a calculated linear correlation.
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The greater experience with dermoscopy for skin cancer detec-
tion, as reflected through more years of dermoscopy practice and
higher number of patients with skin cancer seen per month,
appeared relevant for the reduction in unnecessary biopsies, but
less so for increased melanoma recognition. This concurs with
previous reports showing that even brief dermoscopy training in
inexperienced users can improve the sensitivity of melanoma
recognition,9,32–34 but that the increase in specificity occurred
mostly at an expert level and in specialized centres.18,19,21
A positive impact of dermoscopy on melanoma detection was
expectedly associated with more frequent use of dermoscopy,
across all disease categories, as well as with self-confidence in
dermoscopic skills for pigmented lesions. Expertise, experience
and confidence seem to engage in a positive feedback loop that
enhances the use and the benefits of dermoscopy. This supports
the argument that investment in training and in providing der-
matologists with the opportunity to use dermoscopy could also
improve the efficient use of this technique, for better detection
at lower costs. Consistent with our findings, a recent study35
used a melanoma disease model to demonstrate that adequate
dermoscopy training of dermatologists is cost-effective, in terms
of increasing patients’ quality-adjusted life-years (QALY) and
lowering the medical costs. In this context, it is noteworthy that
only 56% of dermoscopy users reported confidence in their skills
for the diagnosis of pigmented lesions, although this is the main
indication and topic of training in dermoscopy. Optimizing edu-
cational efforts are needed, and the question remains open how
to achieve this. A more detailed analysis of our study data
regarding the patterns of dermoscopy training across Europe,
and their consequence for the dermatologists’ practice, is ongo-
ing and will be reported in the future.
In our study, the use of polarized light dermoscopy and digital
dermoscopy was associated with a perceived benefit of der-
moscopy both for improving melanoma recognition and for
reducing unnecessary excisions. Monitoring melanocytic lesions
by means of sequential digital dermoscopy has been demonstrated
to increase the early detection of thinner melanoma and to lower
the NNE rates, increasing dermoscopy’s cost benefits.12,36–41 This
approach is increasingly recommended by the current European
guidelines of melanoma management.14,16,17 Our results confirm
the importance of access to and use of digital dermoscopy for
increasing the performance of melanoma diagnosis in dermatolo-
gist practice Europe-wide. As 35.7% of our responding dermatol-
ogists reported the use of a form of digital dermoscopy, this leaves
room for significant improvement in the future, while more
research is needed to establish the true cost-effectiveness of wide-
spread use of digital dermoscopy for melanoma early detection.
The classic ABCD rule and pattern analysis were the most fre-
quently reported by dermatologists, likely because they are the
oldest and the most widely taught algorithms. They also repre-
sent two diverging concepts of diagnostic approach, heuristic
and analytical, both subjects of a long-term debate over which is
superior.40,41 It was noteworthy that the use of the ABCD rule
was associated with increased melanoma recognition (Table 1b)
but decreased the likelihood for reducing the number of unnec-
essary biopsies (Table 4); pattern analysis increased both mela-
noma recognition (sensitivity) and the specificity of diagnosis
(Tables 1b and 3b). These findings suggest that pattern analysis
is the best algorithm for increasing accuracy of melanoma diag-
nosis and should be emphasized in the training of dermoscopy.
Nonetheless, using any algorithm vs. no algorithm at all was bet-
ter for increasing melanoma recognition and reducing the num-
ber of unnecessary biopsies.
The impact of dermoscopy on the diagnostic performance for
melanoma varied according to the practice setting for European
dermatologists, with two particular contrasting scenarios standing
out. On the one hand, dermatologists working in individual pri-
vate practices were less likely to report a benefit of dermoscopy to
increase detection of melanomas, but noted greater benefit in
reducing the number of unnecessary biopsies. Conversely, derma-
tologists working in public healthcare facilities experience the
most benefit of dermoscopy in increasing melanoma detection,
but were less likely to report a reduction in the number of biop-
sies. For individual practices, it might be argued that they face a
greater pressure to reduce costs and to limit invasive procedures
for their patients, so the main benefit is perceived in this area.
Dermoscopy appears to fulfil the role of screening for melanoma,
which is an important task of public healthcare facilities, attend-
ing for the vast majority of patients in the European health sys-
tems. However, screening appears to occur without significant
reduction in unnecessary biopsies, and hence of the costs for pub-
lic healthcare – not a good omen in the current landscape of aus-
terity in healthcare budgets. It is thus of vital importance to
examine how to further reduce biopsies by dermoscopy also in
public hospitals. Our prior finding24 had revealed that dermatolo-
gists working in public facilities were the least likely to use der-
moscopy at all, or if they used it, it was less intensively; they were
also the most likely to report the lack of dermoscopy equipment
as a barrier to use dermoscopy. Therefore, proper training and
improved access to dermoscopy equipment, especially digital,
may be the main ways to address this issue in public hospitals.
Our analysis has several limitations. The main one is the sub-
jective nature of the responses. The difference in melanoma
diagnosis numbers or in NNEs through dermoscopy use could
not be verified from the practice records of such a large pan-Eur-
opean sample of respondents. Similarly, our study allowed for a
qualitative, but not quantitative evaluation of the benefit of der-
moscopy for melanoma detection and reducing the unnecessary
biopsies. Nonetheless, our results are consistent with previous
national surveys23,42 and with the evidence of the effect of der-
moscopy on diagnostic accuracy while providing an unprece-
dented insight into dermatologists’ perceptions on the role of
dermoscopy. We acknowledge that responses are likely influ-
enced by the background factors related to the national systems
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of dermatology training and healthcare practice, which are
highly heterogeneous in Europe. However, the free movement of
people, including widespread mobility of the patients, physicians
and medical trainees, is a fundamental concept in Europe, and
medical licenses are virtually automatically recognized in EU
countries. Therefore, a common European vision is needed and
all efforts must be made to ensure that disparities between coun-
tries43 are narrowed and the quality of medical training and care
becomes de facto similar throughout the continent. In this per-
spective, our pan-European results are particularly informative.
Conclusion
Our pan-European survey confirms that dermoscopy is a valuable
tool to improve melanoma recognition and reduce the number of
invasive diagnostic procedures in the daily dermatology practice
across the continent. However, in many cases, this technique is
not used to its full potential. The study brings compelling evi-
dence that enhancing dermoscopy training, especially during der-
matology residency, and increasing dermatologists’ access to
dermoscopy equipment, especially digital dermoscopy, would
contribute significantly to improving the accuracy of melanoma
diagnosis in Europe, with potential to alleviate the current dispar-
ities in early detection and prognosis of this deadly tumour.
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